1. Show article details.

    Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

    GlobeNewswire – 1:06 PM ET 04/01/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares of its common stock at a purchase price of $12.00 per share for total gross proceeds of $15.3 million, before deducting placement agent fees and offering expenses.

  2. Show article details.

    BRIEF-Bellerophon Therapeutics Says Unable To Complete The Required Financial Statements And Audit Required For Filing Its Annual Report On Form 10-K

    Reuters – 6:11 PM ET 03/31/2020

    Bellerophon Therapeutics Inc (BLPH): * Bellerophon Therapeutics Inc (BLPH) - UNABLE TO COMPLETE THE REQUIRED FINANCIAL STATEMENTS AND AUDIT REQUIRED FOR FILING ITS ANNUAL REPORT ON FORM 10-K. * BELLEROPHON THERAPEUTICS (BLPH) - ANTICIPATED THAT FORM 10-K WILL BE FILED ON OR BEFORE THE 15TH CALENDAR DAY FOLLOWING THE PRESCRIBED DUE DATE Source: Further company coverage:

  3. Show article details.

    Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19

    GlobeNewswire – 8:30 AM ET 03/31/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference call and webcast on the INOpulse® inhaled nitric oxide system for the treatment of COVID-19 at 1:00 PM EDT.

  4. Show article details.

    BRIEF-Bellerophon Therapeutics Announces First Patient Treated With Inopulse Inhaled Nitric Oxide Therapy For Covid-19

    Reuters – 10:25 AM ET 03/30/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED WITH INOPULSE® INHALED NITRIC OXIDE THERAPY FOR COVID-19 Source text for Eikon: Further company coverage:

  5. Show article details.

    Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market

    GlobeNewswire – 9:57 AM ET 03/30/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 1,275,000 shares of Bellerophon's common stock, at a purchase price of $12.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

  6. Show article details.

    Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

    GlobeNewswire – 8:00 AM ET 03/30/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system was initiated for the first time in a patient with a diagnosis of the novel coronavirus disease at the University of Miami School of Medicine.

  7. Show article details.

    FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus

    GlobeNewswire – 8:30 AM ET 03/20/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug Administration has granted emergency expanded access allowing its proprietary inhaled nitric oxide delivery system, INOpulse®, to immediately be used for the treatment of COVID-19.

  8. Show article details.

    BRIEF-Bellerophon Announces FDA Agreement On Its Planned Pivotal Phase 3 Study For The Treatment Of Pulmonary Hypertension Associated With Pulmonary Fibrosis

    Reuters – 8:59 AM ET 03/10/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON ANNOUNCES AGREEMENT WITH THE FDA ON ITS PLANNED PIVOTAL PHASE 3 STUDY FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS. * Bellerophon Therapeutics Inc (BLPH) - FINALIZED KEY ELEMENTS OF ITS PLANNED PIVOTAL PHASE 3 STUDY FOR TREATMENT OF PULMONARY HYPERTENSION Source text for Eikon: Further company coverage:

  9. Show article details.

    Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

    GlobeNewswire – 8:30 AM ET 03/10/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced the successful completion of its End-of-Phase 2 Meetings with the U.S. Food and Drug Administration for INOpulse® for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis.

  10. Show article details.

    BRIEF-Bellerophon Reports Positive Top-Line Data From An Ancillary Acute Hemodynamic Study Of Inopulse

    Reuters – 9:21 AM ET 02/18/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON REPORTS POSITIVE TOP-LINE DATA FROM AN ANCILLARY ACUTE HEMODYNAMIC STUDY OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS. * BELLEROPHON - RESULTS SHOWED THAT ACUTE TREATMENT WITH INOPULSE PROVIDED STATISTICALLY, CLINICALLY SIGNIFICANT IMPROVEMENTS IN HEMODYNAMIC PARAMETERS.

  11. Show article details.

    Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

    GlobeNewswire – 8:30 AM ET 02/18/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse® for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis.

  12. Show article details.

    BRIEF-Bellerophon Announces 1-For-15 Reverse Stock Split

    Reuters – 12:04 PM ET 02/07/2020

    Bellerophon Therapeutics Inc (BLPH): * BELLEROPHON ANNOUNCES 1-FOR-15 REVERSE STOCK SPLIT. * Bellerophon Therapeutics Inc (BLPH) - REVERSE STOCK SPLIT IS SCHEDULED TO TAKE EFFECT AFTER MARKET CLOSES ON FEB 7 Source text for Eikon: Further company coverage:

  13. Show article details.

    Bellerophon Announces 1-for-15 Reverse Stock Split

    GlobeNewswire – 12:00 PM ET 02/07/2020

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced the filing of a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of the State of Delaware to effect a 1-for-15 reverse stock split of shares of the Company’s common stock, par value $0.01 per share.

  14. Show article details.

    Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

    GlobeNewswire – 7:00 AM ET 12/17/2019

    Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M Convertible Financing Facility Led By Existing Institutional Shareholders, Extending Cash Runway to 2021 Bellerophon to Host Conference Call and Live Webcast Today at 8:30 AM ET WARREN, N.J., Dec. 17, 2019 ...

  15. Show article details.

    Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

    GlobeNewswire – 8:30 AM ET 11/12/2019

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced positive initial data from an acute, dose escalation, clinical study of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease.

  16. Show article details.

    Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019

    GlobeNewswire – 8:30 AM ET 11/07/2019

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, is presenting data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease at the Pulmonary Fibrosis Foundation Summit 2019, being held November 7-9, 2019, in San Antonio, TX.   ...

  17. Show article details.

    Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results

    GlobeNewswire – 8:30 AM ET 11/06/2019

    Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and nine months ended September 30, 2019.

  18. Show article details.

    Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

    GlobeNewswire – 8:30 AM ET 10/23/2019

    Results Presented in Late-Breaking Abstract as an Oral PresentationPresentation Will Also be Published in the Highlights from CHEST Special Edition Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, presented additional new data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study of INOpulse® for the treatment of Pulmonary Hy...

  19. Show article details.

    Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

    GlobeNewswire – 8:30 AM ET 10/14/2019

    Results to be Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that it will present additional new data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study of INOpulse®...

Page:

Today's and Upcoming Events

  • May
    07

    BLPH to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Apr
    02

    BLPH announced Q4 earnings of per share (vs. ($1.05))

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.